Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells

Cancer Prevention Research

Volumn 2, Issue 7, 2009, Pages 650-657

  Paul, Shiby ^a   Rimando, Agnes M ^b   Hong, Jin Lee ^a   Ji, Yan ^a   Reddy, Bandaru S ^a   Suh, Nanjoo ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; BACTERIUM LIPOPOLYSACCHARIDE; CYCLIN D1; CYCLOOXYGENASE 2; ENDOTOXIN; GAMMA INTERFERON; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLINOSITOL 3 KINASE; PTEROSTILBENE; RESVERATROL; STAT1 PROTEIN; STAT3 PROTEIN; STILBENE DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE ARREST; CELL PROLIFERATION; CELL STRAIN HT29; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE SILENCING; HUMAN; HUMAN CELL; ONCOGENE C MYC; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTI-INFLAMMATORY AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; CYCLOOXYGENASE 2; CYTOKINES; HUMANS; INFLAMMATION; MAP KINASE SIGNALING SYSTEM; MICROSCOPY, FLUORESCENCE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; POLY(ADP-RIBOSE) POLYMERASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STILBENES;

EID: 69249180127     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0224     Document Type: Article

References (48)

1. Schafer M, Werner S. Cancer as an overhealing wound: an old hypothesis revisited. Nat Rev Mol Cell Biol 2008;9:628-638
2. Ulrich S, Loitsch SM, Rau O, et al. Peroxisome proliferator-activated receptor γ as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res 2006;66:7348-7354 (Pubitemid 44197718)
3. Erlinger TP, Platz EA, Rifai N, Helzlsouer KJ. C-reactive protein and the risk of incident colorectal cancer. JAMA 2004;291:585-590 (Pubitemid 38500312)
4. Cianchi F, Cortesini C, Fantappie O, et al. Inducible nitric oxide synthase expression in human colorectal cancer correlation with tumor angiogenesis. Am J Pathol 2003;162:793-801. (Pubitemid 36237488)
5. Ohta T, Takahashi M, Ochiai A. Increased protein expression of both inducible nitric oxide synthase and cyclooxygenase-2 in human colon cancers. Cancer Lett 2006;239:246-253 (Pubitemid 43974868)
6. Rao CV, Kawamori T, Hamid R, Reddy BS. Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor. Carcinogenesis 1999;20:641-644 (Pubitemid 29151301)
7. Takahashi M, Mutoh M, Shoji Y, et al. Suppressive effect of an inducible nitric oxide inhibitor, ONO-1714, on AOM-induced rat colon carcinogenesis. Nitric Oxide 2006;14:130-136 (Pubitemid 43165878)
8. Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 2002;62:165-170
9. Pereg D, Lishner M. Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. J Intern Med 2005;258:115-123 (Pubitemid 41025968)
10. Tuma R. Drugs to prevent colon cancer show promise, but hurdles remain for chemoprevention. J Natl Cancer Inst 2008;100:764-766
11. Kang YJ, Mbonye UR, DeLong CJ, Wada M, Smith WL. Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradation. Prog Lipid Res 2007;46:108-125 (Pubitemid 46661865)
12. Chun KS, Surh YJ. Signal transduction pathways regulating cyclooxygenase-2 expression: potential molecular targets for chemoprevention. Biochem Pharmacol 2004;68:1089-1100
13. Kleinert H, Pautz A, Linker K, Schwarz PM. Regulation of the expression of inducible nitric oxide synthase. Eur J Pharmacol 2004;500:255-266 (Pubitemid 39304013)
14. Kracht M, Saklatvala J. Transcriptional and post-transcriptional control of gene expression in inflammation. Cytokine 2002;20:91-106. (Pubitemid 35370689)
15. Tsatsanis C, Androulidaki A, Venihaki M, Margioris AN. Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 2006;38:1654-1661
16. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene 2007;26:3279-3290 (Pubitemid 46763021)
17. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science 2002;298:1911-1912
18. Saklatvala J. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. Curr Opin Pharmacol 2004;4:372-377 (Pubitemid 38987064)
19. Liu W, Reinmuth N, Stoeltzing O, et al. Cyclooxygenase-2 is up-regulated by interleukin-1β in human colorectal cancer cells via multiple signaling pathways. Cancer Res 2003;63:3632-3636 (Pubitemid 36793046)
20. Lee JC, Laydon JT, McDonnell PC, et al. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 1994;372:739-746
21. Suh N, Paul S, Hao X, et al. Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. Clin Cancer Res 2007;13:350-355 (Pubitemid 46121889)
22. Rimando AM, Kalt W, Magee JB, Dewey J, Ballington JR. Resveratrol, pterostilbene, and piceatannol in Vaccinium berries. J Agric Food Chem 2004;52:4713-4719
23. Roupe KA, Remsberg CM, Yáñez JA, Davies NM. Pharmacometrics of stilbenes: seguing towards the clinic. Curr Clin Pharmacol 2006;1:81-101.
24. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275:218-220 (Pubitemid 127696281)
25. Rimando AM, Cuendet M, Desmarchelier C, Mehta RG, Pezzuto JM, Duke SO. Cancer chemopreventive and antioxidant activities of pterostilbene, a naturally occurring analogue of resveratrol. J Agric Food Chem 2002;50:3453-3457 (Pubitemid 34580577)
26. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 2004;24:2783-2840 (Pubitemid 39409568)
27. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006;5:493-506. (Pubitemid 44136961)
28. Baur JA, Pearson KJ, Price NL, et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006;444:337-342
29. Asensi M, Medina I, Ortega A, et al. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002;33:387-398 (Pubitemid 34786278)
30. Ferrer P, Asensi M, Segarra R, et al. Association between pterostilbene and quercetin inhibits metastatic activity of B16 melanoma. Neoplasia 2005;7:37-47. (Pubitemid 40209469)
31. Remsberg CM, Yanez JA, Ohgami Y, Vega-Villa KR, Rimando AM, Davies NM. Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother Res 2007.
32. Stivala LA, Savio M, Carafoli F, et al. Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 2001;276:22586-22594 (Pubitemid 37410939)
33. Rimando AM, Nagmani R, Feller DR, Yokoyama W. Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor α-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J Agric Food Chem 2005;53:3403-3407 (Pubitemid 40758174)
34. Miura D, Miura Y, Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci 2003;73:1393-1400 (Pubitemid 36798126)
35. Lee HJ, Wislocki A, Goodman C, et al. A novel vitamin D derivative activates bone morphogenetic protein signaling in MCF10 breast epithelial cells. Mol Pharmacol 2006;69:1840-1848 (Pubitemid 43894300)
36. Siddiqui SS, Siddiqui ZK, Uddin S, Minshall RD, Malik AB. p38 MAPK activation coupled to endocytosis is a determinant of endothelial monolayer integrity. Am J Physiol Lung Cell Mol Physiol 2007;292:L114-24. (Pubitemid 46103437)
37. Ono K, Han J. The p38 signal transduction pathway: activation and function. Cell Signal 2000;12:1-13. (Pubitemid 30017963)
38. Kumar S, Boehm J, Lee JC. p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2003;2:717-726
39. Ferrer P, Asensi M, Priego S, et al. Nitric oxide mediates natural polyphenol-induced Bcl-2 down-regulation and activation of cell death in metastatic B16 melanoma. J Biol Chem 2007;282:2880-2890 (Pubitemid 47086274)
40. Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N, Raul F. Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer 2001;39:102-107
41. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-3064
42. Tsai SH, Lin-Shiau SY, Lin JK. Suppression of nitric oxide synthase and the down-regulation of the activation of NFκB in macrophages by resveratrol. Br J Pharmacol 1999;126:673-680
43. Kim YA, Lim SY, Rhee SH, et al. Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β-amyloid-treated C6 glioma cells. Int J Mol Med 2006;17:1069-1075
44. Pan MH, Chang YH, Tsai ML, et al. Pterostilbene suppressed lipopolysaccharide-induced up-expression of iNOS and COX-2 in murine macrophages. J Agric Food Chem 2008;56:7502-7509
45. Ashwell JD. The many paths to p38 mitogen-activated protein kinase activation in the immune system. Nat Rev Immunol 2006;6:532-540
46. Kaminska B. MAPK signalling pathways as molecular targets for anti-inflammatory therapy-from molecular mechanisms to therapeutic benefits. Biochim Biophys Acta 2005;1754:253-262 (Pubitemid 41797706)
47. Reimold AM, Kim J, Finberg R, Glimcher LH. Decreased immediate inflammatory gene induction in activating transcription factor-2 mutant mice. Int Immunol 2001;13:241-248 (Pubitemid 32123958)
48. Hale KK, Trollinger D, Rihanek M, Manthey CL. Differential expression and activation of p38 mitogen-activated protein kinase α, β, γ, and δ in inflammatory cell lineages. J Immunol 1999;162:4246-4252 (Pubitemid 29314814)